Investment objective & strategy
As of April 10, 2025 · prospectusObjective. The Fund seeks long-term capital appreciation.
Strategy. Under normal circumstances, the Fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (Wellington Management). Wellington Managements investment process focuses on stock selection through fundamental analysis. The Fund takes a broad approach to investing in the health care sector. The Fund may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors. The Funds assets will be allocated across the major subsectors of the health care sector, with some representation typically maintained in each major subsector. The Fund will normally invest at least 25% of its total … Under normal circumstances, the Fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (Wellington Management). Wellington Managements investment process focuses on stock selection through fundamental analysis. The Fund takes a broad approach to investing in the health care sector. The Fund may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors. The Funds assets will be allocated across the major subsectors of the health care sector, with some representation typically maintained in each major subsector. The Fund will normally invest at least 25% of its total assets, in the aggregate, in the following industries: pharmaceuticals and biotechnology, medical products and health services. The Fund may invest in securities of companies of any market capitalization.
Top holdings
As of March 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| LILLY ELI and CO | — | $12.63M | 12.09% |
| MERCK & CO | — | $7.01M | 6.71% |
| JOHNSON&JOHNSON | — | $6.32M | 6.05% |
| UNITEDHEALTH GRP | — | $4.30M | 4.11% |
| INTUITIVE SURGICAL INC | — | $3.69M | 3.53% |
| ABBVIE INC | — | $3.33M | 3.19% |
| ABBOTT LABS | — | $3.01M | 2.88% |
| DANAHER CORP | — | $2.96M | 2.84% |
| EDWARDS LIFESCIENCES CORP | — | $2.85M | 2.73% |
| VERTEX PHARMACEUTICALS INC | — | $2.61M | 2.50% |
Portfolio moves
Dec 31, 2025 → Mar 31, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| THE HARTFORD HEALTHCARE FUND · HGHAX, HGHCX, HGHYX, HGHIX, HGHRX, HGHSX, HGHTX, HGHFX, HGHVX | 91% | 0.94% |
| VANGUARD HEALTH CARE FUND · VGHCX, VGHAX | 68% | 0.32% |
| Health Sciences Portfolio | 61% | 0.94% |
Advisers
| Firm | Role |
|---|---|
| Wellington Management Company LLP | Sub-adviser |
| Hartford Funds Management Company, LLC | Adviser |
Footnotes
- Expense ratio as of April 10, 2025, from the fund's prospectus.
- Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
- Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.